People · Operator
Named in public records as an officer, director or promoter · active 2015–2020 · Pharmaceuticals, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Metacrine, Inc. | — | Pharmaceuticals | Series C | $124.8M | $2.3B | 2015 |
| VC23 Investors, LLC | — | Other | Seed | $5.5M | $9.3M | 2018 |
Ronald Evans at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Ronald Evans on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Kristina Burow | 1 | 16 |
| Amir Nashat | 1 | 14 |
| Nathaniel Brinn | 1 | 7 |
| Carol Gallagher | 1 | 6 |
| Robert Adelman | 1 | 5 |
| Neil McDonnell | 1 | 4 |
| Richard Heyman | 1 | 2 |
| Trisha Millican | 1 | 2 |
| Kenneth Song | 1 | 2 |
| Ken Song | 1 | 2 |
| Patricia Millican | 1 | 1 |
| Jackie Hernandez | 1 | 1 |
| Ronald R. Evans | 1 | 1 |
| Christian Gackstatter | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.